88.69 USD
+0.78 (+0.89%)
88.69 USD
0 (0%)
We assign a fundamental rating of 4 out of 10 to MLAB. MLAB was compared to 57 industry peers in the Life Sciences Tools & Services industry. There are concerns on the financial health of MLAB while its profitability can be described as average. MLAB is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
- MLAB had negative earnings in the past year.
- In the past year MLAB had a positive cash flow from operations.
- The reported net income has been mixed in the past 5 years: MLAB reported negative net income in multiple years.
- MLAB had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- MLAB has a better Return On Assets (-0.37%) than 66.67% of its industry peers.
- The Return On Equity of MLAB (-0.88%) is better than 68.42% of its industry peers.
- With a decent Return On Invested Capital value of 3.11%, MLAB is doing good in the industry, outperforming 64.91% of the companies in the same industry.
- Measured over the past 3 years, the Average Return On Invested Capital for MLAB is significantly below the industry average of 13.75%.
- The last Return On Invested Capital (3.11%) for MLAB is above the 3 year average (2.10%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.37% | ||
| ROE | -0.88% | ||
| ROIC | 3.11% |
ROA(3y)-19.07%
ROA(5y)-11.28%
ROE(3y)-58.62%
ROE(5y)-34.92%
ROIC(3y)2.1%
ROIC(5y)1.72%
1.3 Margins
- The Operating Margin of MLAB (6.13%) is better than 61.40% of its industry peers.
- MLAB's Operating Margin has improved in the last couple of years.
- With an excellent Gross Margin value of 62.15%, MLAB belongs to the best of the industry, outperforming 82.46% of the companies in the same industry.
- In the last couple of years the Gross Margin of MLAB has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 6.13% | ||
| PM (TTM) | N/A | ||
| GM | 62.15% |
OM growth 3Y41.92%
OM growth 5Y1.93%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.16%
GM growth 5Y2.74%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so MLAB is destroying value.
- Compared to 1 year ago, MLAB has more shares outstanding
- The number of shares outstanding for MLAB has been increased compared to 5 years ago.
- The debt/assets ratio for MLAB has been reduced compared to a year ago.
2.2 Solvency
- Based on the Altman-Z score of 1.38, we must say that MLAB is in the distress zone and has some risk of bankruptcy.
- MLAB has a worse Altman-Z score (1.38) than 61.40% of its industry peers.
- MLAB has a debt to FCF ratio of 4.69. This is a neutral value as MLAB would need 4.69 years to pay back of all of its debts.
- Looking at the Debt to FCF ratio, with a value of 4.69, MLAB is in the better half of the industry, outperforming 71.93% of the companies in the same industry.
- A Debt/Equity ratio of 0.95 indicates that MLAB is somewhat dependend on debt financing.
- MLAB has a worse Debt to Equity ratio (0.95) than 78.95% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.95 | ||
| Debt/FCF | 4.69 | ||
| Altman-Z | 1.38 |
ROIC/WACC0.29
WACC10.6%
2.3 Liquidity
- A Current Ratio of 2.02 indicates that MLAB has no problem at all paying its short term obligations.
- The Current ratio of MLAB (2.02) is comparable to the rest of the industry.
- A Quick Ratio of 1.44 indicates that MLAB should not have too much problems paying its short term obligations.
- The Quick ratio of MLAB (1.44) is worse than 61.40% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.02 | ||
| Quick Ratio | 1.44 |
3. Growth
3.1 Past
- The earnings per share for MLAB have decreased strongly by -104.68% in the last year.
- MLAB shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -39.16% yearly.
- MLAB shows a small growth in Revenue. In the last year, the Revenue has grown by 7.39%.
- The Revenue has been growing by 15.41% on average over the past years. This is quite good.
EPS 1Y (TTM)-104.68%
EPS 3Y-62.71%
EPS 5Y-39.16%
EPS Q2Q%-43.61%
Revenue 1Y (TTM)7.39%
Revenue growth 3Y9.35%
Revenue growth 5Y15.41%
Sales Q2Q%5.02%
3.2 Future
- Based on estimates for the next years, MLAB will show a very strong growth in Earnings Per Share. The EPS will grow by 231.94% on average per year.
- MLAB is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.49% yearly.
EPS Next Y2707.43%
EPS Next 2Y382.35%
EPS Next 3Y231.94%
EPS Next 5YN/A
Revenue Next Year3.09%
Revenue Next 2Y4.17%
Revenue Next 3Y4.49%
Revenue Next 5YN/A
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
- MLAB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- With a Price/Forward Earnings ratio of 54.46, MLAB can be considered very expensive at the moment.
- MLAB's Price/Forward Earnings is on the same level as the industry average.
- Compared to an average S&P500 Price/Forward Earnings ratio of 24.26, MLAB is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 54.46 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, MLAB is valued cheaply inside the industry as 85.96% of the companies are valued more expensively.
- MLAB's Price/Free Cash Flow ratio is rather cheap when compared to the industry. MLAB is cheaper than 98.25% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 13.13 | ||
| EV/EBITDA | 16.06 |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- MLAB has a very decent profitability rating, which may justify a higher PE ratio.
- A more expensive valuation may be justified as MLAB's earnings are expected to grow with 231.94% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y382.35%
EPS Next 3Y231.94%
5. Dividend
5.1 Amount
- With a yearly dividend of 0.76%, MLAB is not a good candidate for dividend investing.
- Compared to an average industry Dividend Yield of 0.09, MLAB pays a better dividend. On top of this MLAB pays more dividend than 100.00% of the companies listed in the same industry.
- Compared to an average S&P500 Dividend Yield of 1.89, MLAB's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.76% |
5.2 History
- The dividend of MLAB decreases each year by -0.50%.
- MLAB has been paying a dividend for at least 10 years, so it has a reliable track record.
- MLAB has not decreased its dividend for at least 10 years, so it has a reliable track record of non decreasing dividend.
Dividend Growth(5Y)-0.5%
Div Incr Years0
Div Non Decr Years21
5.3 Sustainability
- MLAB has negative earnings and hence a negative payout ratio. The dividend may be in danger.
DP-222.26%
EPS Next 2Y382.35%
EPS Next 3Y231.94%
88.69
+0.78 (+0.89%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)11-06 2025-11-06/amc
Earnings (Next)02-03 2026-02-03
Inst Owners92.73%
Inst Owner Change0.08%
Ins Owners5.44%
Ins Owner Change3.69%
Market Cap489.57M
Revenue(TTM)245.25M
Net Income(TTM)-1.57M
Analysts80
Price Target96.9 (9.26%)
Short Float %5.43%
Short Ratio2.21
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.76% |
Yearly Dividend0.64
Dividend Growth(5Y)-0.5%
DP-222.26%
Div Incr Years0
Div Non Decr Years21
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)133.29%
Min EPS beat(2)90.84%
Max EPS beat(2)175.74%
EPS beat(4)2
Avg EPS beat(4)-16.43%
Min EPS beat(4)-217.83%
Max EPS beat(4)175.74%
EPS beat(8)5
Avg EPS beat(8)416.54%
EPS beat(12)6
Avg EPS beat(12)229.18%
EPS beat(16)8
Avg EPS beat(16)167.02%
Revenue beat(2)0
Avg Revenue beat(2)-2.79%
Min Revenue beat(2)-3.63%
Max Revenue beat(2)-1.95%
Revenue beat(4)1
Avg Revenue beat(4)-0.43%
Min Revenue beat(4)-3.63%
Max Revenue beat(4)4.83%
Revenue beat(8)3
Avg Revenue beat(8)-0.19%
Revenue beat(12)3
Avg Revenue beat(12)-1.93%
Revenue beat(16)6
Avg Revenue beat(16)0.23%
PT rev (1m)0%
PT rev (3m)7.34%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-6.74%
EPS NY rev (1m)0%
EPS NY rev (3m)9.16%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.46%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.4%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 54.46 | ||
| P/S | 2 | ||
| P/FCF | 13.13 | ||
| P/OCF | 11.88 | ||
| P/B | 2.74 | ||
| P/tB | N/A | ||
| EV/EBITDA | 16.06 |
EPS(TTM)-0.27
EYN/A
EPS(NY)1.63
Fwd EY1.84%
FCF(TTM)6.76
FCFY7.62%
OCF(TTM)7.47
OCFY8.42%
SpS44.43
BVpS32.33
TBVpS-18.71
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.37% | ||
| ROE | -0.88% | ||
| ROCE | 3.94% | ||
| ROIC | 3.11% | ||
| ROICexc | 3.28% | ||
| ROICexgc | 14.87% | ||
| OM | 6.13% | ||
| PM (TTM) | N/A | ||
| GM | 62.15% | ||
| FCFM | 15.21% |
ROA(3y)-19.07%
ROA(5y)-11.28%
ROE(3y)-58.62%
ROE(5y)-34.92%
ROIC(3y)2.1%
ROIC(5y)1.72%
ROICexc(3y)2.32%
ROICexc(5y)2.16%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)2.66%
ROCE(5y)2.18%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y111.19%
ROICexc growth 5Y22.93%
OM growth 3Y41.92%
OM growth 5Y1.93%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.16%
GM growth 5Y2.74%
F-Score5
Asset Turnover0.57
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.95 | ||
| Debt/FCF | 4.69 | ||
| Debt/EBITDA | 4.27 | ||
| Cap/Depr | 15.81% | ||
| Cap/Sales | 1.6% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 103.47% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.02 | ||
| Quick Ratio | 1.44 | ||
| Altman-Z | 1.38 |
F-Score5
WACC10.6%
ROIC/WACC0.29
Cap/Depr(3y)13.3%
Cap/Depr(5y)13.77%
Cap/Sales(3y)1.71%
Cap/Sales(5y)1.8%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-104.68%
EPS 3Y-62.71%
EPS 5Y-39.16%
EPS Q2Q%-43.61%
EPS Next Y2707.43%
EPS Next 2Y382.35%
EPS Next 3Y231.94%
EPS Next 5YN/A
Revenue 1Y (TTM)7.39%
Revenue growth 3Y9.35%
Revenue growth 5Y15.41%
Sales Q2Q%5.02%
Revenue Next Year3.09%
Revenue Next 2Y4.17%
Revenue Next 3Y4.49%
Revenue Next 5YN/A
EBIT growth 1Y22.54%
EBIT growth 3Y55.19%
EBIT growth 5Y17.63%
EBIT Next Year177.2%
EBIT Next 3Y46.94%
EBIT Next 5YN/A
FCF growth 1Y2.55%
FCF growth 3Y6.74%
FCF growth 5Y10.67%
OCF growth 1Y3.18%
OCF growth 3Y6.07%
OCF growth 5Y11.64%
MESA LABORATORIES INC / MLAB FAQ
Can you provide the ChartMill fundamental rating for MESA LABORATORIES INC?
ChartMill assigns a fundamental rating of 4 / 10 to MLAB.
What is the valuation status of MESA LABORATORIES INC (MLAB) stock?
ChartMill assigns a valuation rating of 5 / 10 to MESA LABORATORIES INC (MLAB). This can be considered as Fairly Valued.
How profitable is MESA LABORATORIES INC (MLAB) stock?
MESA LABORATORIES INC (MLAB) has a profitability rating of 6 / 10.
What is the financial health of MESA LABORATORIES INC (MLAB) stock?
The financial health rating of MESA LABORATORIES INC (MLAB) is 3 / 10.
Can you provide the expected EPS growth for MLAB stock?
The Earnings per Share (EPS) of MESA LABORATORIES INC (MLAB) is expected to grow by 2707.43% in the next year.